|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM346975522 |
| 003 |
DE-627 |
| 005 |
20231226032729.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.109142
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1156.xml
|
| 035 |
|
|
|a (DE-627)NLM346975522
|
| 035 |
|
|
|a (NLM)36182049
|
| 035 |
|
|
|a (PII)S1521-6616(22)00223-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Baccelli, F
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Transplantation to save the life, TSH screening to save the brain
|b A report and brief literature review of autoimmune thyroid disease after HSCT for severe combined immunodeficiency
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 28.11.2022
|
| 500 |
|
|
|a Date Revised 26.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022. Published by Elsevier Inc.
|
| 520 |
|
|
|a Autoimmune thyroid disease has been described as a complication of HSCT for different indications and as a manifestation of inborn errors of immunity, like SCID. A 1-month female was diagnosed with RAG1-mutated SCID and received allogenic HSCT. She developed autoimmune hypothyroidism 5 months after transplantation and was treated with levo-thyroxine with a good response. Autoimmune thyroid disease can develop after HSCT during the immune reconstitution phase, leading to potentially severe neurological and growth impairment, particularly in SCID patients, often transplanted during the first year of life. Recommendations regarding early and frequent vigilance for thyroid function are needed in these patients
|
| 650 |
|
4 |
|a Case Reports
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Autoimmunity
|
| 650 |
|
4 |
|a Hematopoietic stem cells transplantation
|
| 650 |
|
4 |
|a Infant
|
| 650 |
|
4 |
|a Severe combined immunodeficiency
|
| 650 |
|
4 |
|a Thyroid
|
| 650 |
|
7 |
|a Thyrotropin
|2 NLM
|
| 650 |
|
7 |
|a 9002-71-5
|2 NLM
|
| 700 |
1 |
|
|a Ortolano, R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Conti, F
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Soncini, E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Baronio, F
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Masetti, R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ferrari, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cassio, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pession, A
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 245(2022) vom: 29. Dez., Seite 109142
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:245
|g year:2022
|g day:29
|g month:12
|g pages:109142
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.109142
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 245
|j 2022
|b 29
|c 12
|h 109142
|